Efficacy of Bisphosphonates in Reducing Fracture Risk Among Postmenopausal Women With Osteoporosis
Author Information
Author(s): Muacevic Alexander, Adler John R, Ullah Mutea, Arshad Junaid, Anwar Uzma, Khan Shehriyar, Amjad Anum, Zeb Arsalan, Majid Maham
Primary Institution: Hayatabad Medical Complex, Peshawar, PAK
Hypothesis
This study aimed to assess the efficacy of bisphosphonates in reducing fracture risk among postmenopausal women with osteoporosis.
Conclusion
Bisphosphonates effectively lower fracture risk in postmenopausal women with osteoporosis.
Supporting Evidence
- The incidence of new fractures decreased significantly from 37.48% before therapy to 14.85% post-therapy.
- Logistic regression analysis indicated that age and baseline BMD T-score were significantly associated with fracture risk reduction.
- The average duration of bisphosphonate medication was 2.30 years.
Takeaway
This study shows that taking bisphosphonates helps older women with weak bones have fewer broken bones.
Methodology
A retrospective cohort study was conducted analyzing data from postmenopausal women aged 50 and older diagnosed with osteoporosis and treated with bisphosphonates for at least a year.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The retrospective design may introduce selection bias, and reliance on patient records could lead to inaccuracies in medication adherence.
Participant Demographics
Participants were postmenopausal women aged 50 and older, with a mean age of 65.40 years.
Statistical Information
P-Value
<0.0001
Confidence Interval
95% CI: 1.02 - 1.09
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website